%0 Journal Article
%T The benefits of exercise training in interstitial lung disease: protocol for a multicentre randomised controlled trial
%A Leona Dowman
%A Christine F McDonald
%A Catherine Hill
%A Annemarie Lee
%A Kathryn Barker
%A Claire Boote
%A Ian Glaspole
%A Nicole Goh
%A Annemarie Southcott
%A Angela Burge
%A Rebecca Ndongo
%A Alicia Martin
%A Anne E Holland
%J BMC Pulmonary Medicine
%D 2013
%I BioMed Central
%R 10.1186/1471-2466-13-8
%X One hundred and sixteen participants with interstitial lung disease recruited from three tertiary institutions will be randomised to either an exercise training group (supervised exercise training twice weekly for eight weeks) or a usual care group (weekly telephone support). The 6-minute walk distance, peripheral muscle strength, health-related quality of life, dyspnoea, anxiety and depression will be measured by a blinded assessor at baseline, immediately following the intervention and at six months following the intervention. The primary outcome will be change in 6-minute walk distance following the intervention, with planned subgroup analyses for participants with idiopathic pulmonary fibrosis, dust-related interstitial lung disease and connective-tissue related interstitial lung disease. The effects of disease severity on outcomes will be evaluated using important markers of disease severity and survival, such as forced vital capacity, carbon monoxide transfer factor and pulmonary hypertension.This trial will provide certainty regarding the role of exercise training in interstitial lung disease and will identify at what time point within the disease process this treatment is most effective. The results from this study will inform and optimise the clinical management of people with interstitial lung disease.Australian New Zealand Clinical Trials Registry ACTRN12611000416998The interstitial lung diseases (ILDs) are a disabling and diverse group of chronic lung conditions that have been broadly classified into four groups: ILD of known cause such as occupational or environmental exposures and/or collagen vascular disease; granulomatous ILD such as sarcoidosis; idiopathic interstitial pneumonias including idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP); and other rare forms of ILD including lymphangioleiomyomatosis, pulmonary Langerhans¡¯ cell histiocytosis/histiocytosis X, and eosinophilic pneumonia [1]. Many ILDs are characterised
%K Interstitial lung diseases
%K Diffuse parenchymal lung diseases
%K Idiopathic pulmonary fibrosis
%K Idiopathic interstitial pneumonias
%K Asbestosis
%K Sarcoidosis
%K Hypersensitivity pneumonitis
%K Connective tissue diseases
%K Exercise
%K Rehabilitation
%U http://www.biomedcentral.com/1471-2466/13/8